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The positive transcription elongation factor b (P-TEFb) is involved
in physiological and pathological events including inﬂammation,
cancer, AIDS, and cardiac hypertrophy. The balance between its
active and inactive form is tightly controlled to ensure cellular in-
tegrity. We report that the transcriptional repressor CTIP2 is a major
modulator of P-TEFb activity. CTIP2 copuriﬁes and interacts with
an inactive P-TEFb complex containing the 7SK snRNA and HEXIM1.
CTIP2 associates directly with HEXIM1 and, via the loop 2 of the
7SK snRNA, with P-TEFb. In this nucleoprotein complex, CTIP2 sig-
niﬁcantly represses the Cdk9 kinase activity of P-TEFb. Accord-
ingly, we show that CTIP2 inhibits large sets of P-TEFb- and 7SK
snRNA-sensitive genes. In hearts of hypertrophic cardiomyopathic
mice, CTIP2 controls P-TEFb-sensitive pathways involved in the
establishment of this pathology. Overexpression of the β-myosin
heavy chain protein contributes to the pathological cardiac wall
thickening. The inactive P-TEFb complex associates with CTIP2 at
the MYH7 gene promoter to repress its activity. Taken together,
our results strongly suggest that CTIP2 controls P-TEFb function in
physiological and pathological conditions.
Discovered in 1995 (1), P-TEFb (CyclinT1/Cdk9) is involvedin physiological and pathological transcriptionally regulated
events such as cell growth, differentiation, cancer, cardiac hy-
pertrophy, and AIDS (for review, see refs. 2 and 3). It has been
suggested to be required for transcription of most RNA poly-
merase II-dependent genes. However, a recent study suggests
that a subset of cellular genes are distinctively sensitive to Cdk9
inhibition (4). P-TEFb is dynamically regulated by both positive
and negative regulators. In contrast to Brd4, which is associated
with the active form of P-TEFb (5, 6), the 7SK small nuclear
RNA (7SK snRNA) and HEXIM1 inhibit Cdk9 activity in the
inactive P-TEFb complex (7–10). P-TEFb elongation complexes
are crucial for HIV-1 gene transactivation and viral replication.
Recently, new P-TEFb complexes containing the HIV-1 Tat
protein have been characterized (11, 12), providing evidence for
the recruitment of an inactive Tat/P-TEFb complex to the HIV-1
promoter (13). However, deﬁning the diverse nature and func-
tions of the different P-TEFb complexes will require further
investigations. The cellular protein CTIP2 (Bcl11b) has been
highlighted as a key transcription factor for thymocyte (14, 15)
and neuron development (16), odontogenesis (17), cancer evo-
lution (18), and HIV-1 gene silencing (19). Besides AIDS, hy-
pertrophic cardiomyopathy is a well-described P-TEFb–dependent
pathology (for review, see refs. 20 and 21).
Here, we report that CTIP2 represses P-TEFb function as part
of an inactive P-TEFb complex. In hearts of hypertrophic car-
diomyopathic mice, CTIP2 controls P-TEFb-sensitive pathways
involved in the establishment of this pathology. Together with
the inactive P-TEFb complex, CTIP2 associates with the β-myosin
heavy chain promoter to repress its activity. Thereby, CTIP2 might
contribute to the regulation of the size of heart sarcomeres in
physiological or pathological conditions.
Results
CTIP2 Is Associated with the Inactive P-TEFb Complex. First, we in-
vestigated, whether or not CTIP2 associates with one of the
previously described P-TEFb complexes. We performed immu-
noprecipitation experiments, revealing that CTIP2 coimmuno-
precipitates with the CyclinT1 and Cdk9 components of the P-
TEFb complex (Fig. 1A). To further deﬁne the CTIP2-contain-
ing complexes, we separated the previously described P-TEFb
complexes by gel ﬁltration chromatography (Fig. 1B). As shown in
Fig. 1B, Cdk9 was detected in the low molecular weight (LMW)
complex (”free” P-TEFb complex) and in the high molecular
weight (HMW) complex that coeluted with HEXIM1 and the 7SK
snRNA. Interestingly, we found CTIP2 in those latter fractions
containing the HMW P-TEFb complex (Fig. 1B). These obser-
vations suggested that CTIP2 may be part of an inactive HEXIM1/
7SK-including P-TEFb complex. To conﬁrm this hypothesis, we
performed additional coimmunoprecipitation experiments target-
ing the active and the inactive form of P-TEFb. We found that
CTIP2 copuriﬁed with CyclinT1, Cdk9, HEXIM1, and 7SK but
not with Brd4, making CTIP2 a previously undescribed compo-
nent of the inactive P-TEFb complex. Confocal observations further
conﬁrmed the colocalization of CTIP2, P-TEFb, and HEXIM1 in
the previously described CTIP2-induced nuclear structures (22)
(Fig. S1). As suggested by the gel ﬁltration elution proﬁle, CTIP2
was not found in the active Brd4/P–TEFb complexes. The 7SK
snRNA functions as a scaffold RNA facilitating the interaction
between HEXIM1 and P-TEFb. To investigate how CTIP2
associates with the inactive P-TEFb complex, we performed
coimmunoprecipitation experiments following RNase treatment
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to degrade the 7SK snRNA (Fig. 1D). As previously described,
degradation of the 7SK snRNA (Fig. 1D, Right) induced the
dissociation of P-TEFb and HEXIM1 (Fig. 1D, Left, column 5 vs.
3). However, CTIP2 remained associated with HEXIM1 upon
RNase treatment, suggesting that CTIP2 directly interacts with
HEXIM1 and that the 7SK RNA is required to associate with P-
TEFb. These biochemical observations were supplemented by
functional experiments. Because the HIV-1 LTR is a bonaﬁde P-
TEFb–sensitive promoter, we quantiﬁed its activity upon CTIP2
knockdown, Tat transactivation, and P-TEFb inhibition. We ob-
served that knocking down CTIP2 increased the Tat-dependent
transcriptional activity of the HIV-1 promoter, suggesting that
endogenous CTIP2 might contribute to the repression of Tat by
repressing P-TEFb function (Fig. 1E). In support of this hypothesis,
treatments with Flavopyridol, a potent P-TEFb inhibitor,
abrogated this synergistic transcriptional activation. Therefore, we
conclude that CTIP2 may contribute to P-TEFb repression in the
inactive form of the P-TEFb complex. Along this line, we further
investigated CTIP2 function in this P-TEFb-, HEXIM1-, and
7SK snRNA-including nucleoprotein complex (Fig. 2).
CTIP2 Interacts with the 7SK snRNA. First, gel shift experiments were
performed to deﬁne whether CTIP2 interacts with the 7SK snRNA
in vitro. As shown in Fig. S2, increasing amounts of puriﬁed GST-
CTIP2 protein shifted increasing amounts of 32P-labeled 7SK
snRNA, indicating that CTIP2 interacts with the 7SK in vitro. As
a control, GST-CTIP2 did not bind to TAR RNA in vitro. To
deﬁne whether this interaction also exists in vivo, we performed
immunoprecipitations of CTIP2-associated complexes and probed
for the presence of 7SK RNA by RT-PCR. We found that the 7SK
snRNA copuriﬁed with CTIP2, suggesting that this association
exists in vivo (Fig. 2A). Micro scale thermophoresis experiments
conﬁrmed this result and allowed us to precise the domain of 7SK
involved in this interaction. CTIP2 associates with the Loop 2
domain of the 7SK snRNA, but not with a point-mutated Loop 2
(Fig. 2 B and C). We next investigated which domain of CTIP2 is
involved in the interaction with 7SK and P-TEFb. To do so, we
performed immunoprecipitation experiments with truncated
forms of CTIP2 (Fig. 2D). This mapping conﬁrmed the need of
the 7SK snRNA for the interaction with P-TEFb but not with
HEXIM1 (Fig. 2D and Fig. S3). Indeed, a CTIP2 mutant lacking
amino acids 355–813 was unable to associate with 7SK snRNA
and P-TEFb, but still associated with HEXIM1 (Fig. 2D, column
3). Moreover, we identiﬁed the domain from 349 to 475 aa of
CTIP2 as the potential interface for P-TEFb binding and thereby
for the 7SK snRNA interaction (Fig. S4). Surprisingly, the deletion
of the 717 ﬁrst amino acids (out of 813) of CTIP2 was needed to
release the interaction with HEXIM1 (Fig. 2D, column 1). Next, we
tested whether or not CTIP2 regulates P-TEFb activity.
CTIP2 Inhibits Cdk9-Mediated Phosphorylation. To explain CTIP2-
mediated repression of the P-TEFb function, we ﬁrst hypothe-
sized that CTIP2 may favor P-TEFb recruitment into the inactive
complex. CyclinT1 immunoprecipitation experiments were per-
formed to conﬁrm this hypothesis. Surprisingly, CTIP2 over-
expression did not favor recruitment of P-TEFb into the inactive
7SK snRNA-containing complex (Fig. 2E). Because the amount
of P-TEFb in the inactive complex was not impacted by CTIP2,
we next tested the inhibition of the P-TEFb kinase activity. We
ﬁrst quantiﬁed the Cdk9 kinase activity of the CyclinT1-immu-
noprecipitated complex in the presence or absence of CTIP2
overexpression. As shown in Fig. 2F, CTIP2 overexpression sig-
niﬁcantly inhibits Cdk9 activity (Fig. 2F and Fig. S5). To conﬁrm
that this repression also occurs in physiological conditions, we
analyzed the global level of RNA Pol II serine 2 phosphorylation
in CTIP2 knockdown cells. Accordingly, higher levels of RNA
Pol II serine 2 phosphorylation were observed in CTIP2-depleted
cells (Fig. 2G). These observations suggest that CTIP2 represses
P-TEFb function by inhibiting Cdk9 activity.
CTIP2-Including Complexes Containing P-TEFb– and Chromatin-Modifying
Enzymes Are Mutually Exclusive. We have reported that CTIP2
silences HIV-1 gene expression by the recruitment of HDAC1,
HDAC2, and SUV39H1 to the viral promoter (19). To examine the
existence of multiple CTIP2 complexes, we performed sequential
immunoprecipiation experiments. For this purpose, CTIP2 associ-
ated complexes (IP1) were further immunoprecipitated with anti-
HEXIM1 or anti-HDAC2 antibodies to discriminate between
potential P-TEFb– and chromatin-modifying enzyme-containing
complexes, respectively (IP2). As shown in Fig. 3, HDAC2 and
Suv39H1 were excluded from the P-TEFb complex whereas neither
Cdk9, CyclinT1, nor HEXIM1 was found in the complex containing
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Fig. 1. CTIP2 is associated with the inactive P-TEFb complex. (A) HEK293T
cells expressing FLAG-CTIP2 were lysed and immunoprecipitated with anti-
CyclinT1 antibody or with nonimmune serum IgG (NIS). Input and immu-
noprecipitated proteins were probed with anti-FLAG (f-CTIP2), anti-CyclinT1,
and anti-Cdk9 antibodies. (B) Protein complexes from microglial cell nuclear
extracts were separated in 29 fractions by HPLC gel ﬁltration. Each collected
fraction was subjected to Western blot analysis with the indicated antibodies
and processed for 7SK detection by RT-PCR. Before all separations, the column
was calibrated with protein standards (dextran blue, 2,000 kDa, fraction 9;
thyroglobulin, 669 kDa, fraction 14; ferritin, 440 kDa, fraction 17). (C) HEK293T
cells expressing FLAG-CTIP2 were lysed and immunoprecipitated with anti-FLAG
antibody. Input (lines 1 and 2) and immunoprecipitated proteins (lines 3 and 4)
were probed with anti-FLAG, anti-Brd4, anti-CyclinT1, anti-Cdk9, and anti-
HEXIM1 antibodies. The presence of the 7SK snRNA was assessed by RT-PCR
ampliﬁcation. (D) Cellular extracts were treated (+) or not (−) with RNase
before being subjected to immunoprecipitation with anti-Hexim1 antibody or
nonimmune serum (NIS) as indicated. Inputs (line 1) and immunoprecipitated
proteins (lines 2, 3, 4, and 5) were probed with anti-CTIP2, anti-CyclinT1, anti-
Cdk9, and anti-HEXIM1 antibodies. 7SK snRNA degradation was controled by
RT-PCR. (E) Cells were transfected with the LTR-LUC (HIV-1 promoter) epizomal
reporter construct in the presence of Tat and/or sh-CTIP2 plasmids or the re-
spective control constructs. Cells were treated with 30 or 100 nM ﬂavopyridol
24 h posttransfection and subjected to luciferase assays 48 h posttransfection.
Efﬁciencies of knockdown and overexpression were controlled by Western
blot as in Fig. 2 F and G. Results are representative for at least three in-
dependent experiments performed in triplicates.
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the chromatin-modifying enzymes. These data demonstrate that
CTIP2 associates at least with two distinct nuclear complexes.
CTIP2 Regulates P-TEFb–Sensitive Genes. To validate the model
emerging from our observations, establishing CTIP2 as a negative
regulatory component of P-TEFb, we examined the genome-wide
transcriptional consequences of a CTIP2 knockdown in microglial
and HEK293 cells. Using DNA microarray analysis, genes whose
expression was modulated by siRNA-mediated deletion of CTIP2
(Dataset S1) were compared with those regulated by the ex-
pression of a dominant negative mutant of Cdk9 (dnCdk9) (4).
Hierarchical clustering of these genes revealed a signiﬁcant
anticorrelation between the two gene expression proﬁles (Fig.
4A). Clustering of highly coregulated genes (−1>Log2 > 1 in
both gene proﬁles) revealed that 86% of the Cdk9 sensitive
genes are inversely regulated by the CTIP2 knockdown (Fig. 4B
and Fig. S6). The comparison of the genes signiﬁcantly ðP< 0:05Þ
regulated by CTIP2 overexpression, knockdown, and dnCdk9
expression in HEK293 cells conﬁrmed the observations made in
microglial cells (Figs. 4 C–E). The 25% of the genes whose ex-
pression was signiﬁcantly ðP< 0:05Þ altered following CTIP2 knock-
down or overexpression were also sensitive to dnCdk9, and, among
them, 76% were regulated consistently with a Cdk9-inhibitory ac-
tivity of CTIP2. Note that the vast majority of these consistently
regulated genes are repressed upon dnCdk9 expression, in con-
cordance with the elongation-activating role of P-TEFb. Besides
that, we identiﬁed 14% (microglial cells) and 24% (HEK293 cells)
of the CTIP2 target genes to be divergently regulated upon dnCdk9
expression, pointing at a different mechanism, where CTIP2 can
potentially also contribute to Cdk9 activation (Fig. 4D). Whether
this mode of action is direct or indirect needs to be further
investigated.
CTIP2 Regulates 7SK snRNA-Sensitive Genes. Because 7SK snRNA
has been described as a key inhibitor of P-TEFb, we next com-
pared the 7SK- and the CTIP2-dependent transcriptome (Fig. 4
F and G and Datasets S2–S5). About 48% of the genes were in-
versely affected by CTIP2 overexpression or 7SK knockdown. This
observation is consistent with a P-TEFb–repressive role of CTIP2
and coincides with our model, in which both 7SK snRNA and
CTIP2 contribute to the inactivation of Cdk9. Surprisingly, 52% of
the genes were found to be similarly regulated following CTIP2
overexpression or 7SK knockdown, suggesting that CTIP2 regu-
lates a subset of 7SK-sensitive genes by a still unknown, P-
TEFb–independent mechanism (Fig. 4F).
CTIP2 Regulates Cdk9-Sensitive Genes Modulated During Cardiac
Hypertrophy in Mouse. As a compound of the inactive P-TEFb
complex, CTIP2 should contribute to the regulation of P-TEFb–
related physiopathological events. To investigate the physiolog-
ical relevance of our observations, we focused on one of the
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Fig. 2. Associated with the 7SK snRNA, CTIP2 inhibits Cdk9-mediated phos-
phorylation. (A) HEK293T cells were lysed and subjected to immunoprecipi-
tations with indicated antibodies. The presence of 7SK snRNA was quantiﬁed
by RT-Q-PCR after complex elution and RNA extraction. (B) Secondary struc-
tures of 7SK L2 and the mutant 7SK L2 m137 were calculated using Assemble
software (version 2.1); nucleotides are indicated by color code and numbered
with respect to their position in full-length 7SK RNA and arrows indicate
mutations in m137. (C) MST analyses were performed with cellular extracts
containing increasing amounts of FLAG-CTIP2 and Fam6-labeled 7SK L2 and
7SK L2 m137. The FLAG-CTIP2 amount was monitored by Western blot using
anti-FLAG antibody, and the total protein amount was visualized by Coo-
massie staining. The highest CTIP2 concentration was abitrarily set to 1,000. (D)
Mock, FLAG-CTIP2 wild-type, or FLAG-CTIP2 constructs transfected HEK293T
cells were lysed and subjected to immunoprecipitation with anti-FLAG anti-
body. The presence of 7SK snRNA was quantiﬁed by RT-Q-PCR after complex
elution and RNA extraction. Detection of immunoprecipitated proteins was
determined by Western blot analysis with the indicated antibodies. (E) Mock
or FLAG-CTIP2 transfected cells were lysed and subjected to immunoprecipi-
tations with the indicated antibodies. The presence of 7SK snRNA was quan-
tiﬁed by RT-Q-PCR after complex elution and RNA extraction. (F) FLAG-CTIP2
or mock transfected cells were lysed and subjected to immunoprecipitation
with anti-CyclinT1 antibody. Immunoprecipitated proteins were incubated for
1 h at 30 °C with GST-CTD and 1 μCi of 32P-labeled ATP. After SDS/PAGE, la-
beled GST-CTD and endogenous Cdk9 were detected by autoradiography.
Quantiﬁcation of the signals was performed using ImageJ software. The
presence of the indicated proteins was determined by Western blot analysis
with the indicated antibodies. The amount of GST-CTD was assessed by Coo-
massie staining. Speciﬁcity for the GST-CTD substrate was controlled by using
mutated GST-CTD (Fig. S5). (G) Extracts fromWT or CTIP2 knockdown cell lines
were subjected to Western blot analysis with the indicated antibodies.
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best-characterized P-TEFb–associated pathologies: hypertrophic
cardiomyopathy (HCM). HCM was triggered by phenylephrin
(PE) administration to adult mice for 15 d. PE is an alpha-
adrenergic receptor agonist known to trigger cardiac hypertrophy
in mice. Gene expression proﬁles from HCM mice were com-
pared with those obtained upon Cdk9 overexpression and CTIP2
knockdown (Fig. 5). Cdk9 overexpression regulated half of the
HCM-modulated genes, conﬁrming the inﬂuence of P-TEFb on
this speciﬁc pathological gene expression pattern (Fig. 5A and
Dataset S6). We observed a signiﬁcant correlation between the
gene expression levels from both conditions (Fig. 5B). By com-
paring this cluster of genes with CTIP2-sensitive genes, we ob-
served that 50% of the Cdk9-sensitive HCM genes were
consistently regulated by CTIP2 knockdown (Fig. 5 C and D and
Dataset S7). Interestingly, key HCM pathways are enriched in
the CTIP2/Cdk9 cluster of modulated genes (Fig. 5E). We
found that the gene of the sarcomeric β-myosin heavy chain
(MYH7) was regulated by CTIP2 consistently with a repression
of Cdk9 function (Fig. 5F). Moreover, a network analysis of the
HCM Cdk9- and CTIP2-sensitive genes highlights the major
impact of CTIP2 on the regulation of cardiac hypertrophy (Fig.
5G). Indeed, key HCM pathways, such as the MAPK, the Ca2+/
Calmodulin, the NF-κB/NFAT, and the PI3K/AkT pathways, are
regulated by CTIP2 (Fig. 5G). We found endogenous CTIP2,
CyclinT1, Cdk9, and HEXIM1 bound to the MYH7 promoter
(Fig. 6A). Moreover, overexpressed CTIP2 bound to the MYH7
proximal promoter but not to −1,000 bp and −2,000 bp upstream
or +2,000 bp downstream of the transcription start site (Fig. 6B).
Accordingly, with our model, the recruitment of Cdk9 (Fig. 6,
column 3), CyclinT1 (Fig. 6, column 4), and HEXIM1 (Fig. 6,
column 5) is favored by the presence of CTIP2. These observa-
tions argue for a CTIP2-mediated anchorage of an inactive P-
TEFb complex at the MYH7 promoter and suggest a major in-
ﬂuence of CTIP2 in the control of the size of heart sarcomeres.
The proposed mechanistic model is presented in Fig. 7.
Discussion
The cellular factor CTIP2 is a key transcriptional repressor in-
volved in development (14–17, 23), T lineage commitment (15,
24), cancer (18, 25), and HIV-1 gene silencing (19). In associa-
tion with chromatin modifying enzymes, CTIP2 promotes the
establishment of a local heterochromatin environment at target
promoters such as the cellular p21 gene promoter (26) and the
viral HIV-1 gene promoter (19, 22, 27). Interestingly, both genes
have been reported to be highly sensitive to the P-TEFb elon-
gation complex (28–30). To secure the cell integrity, P-TEFb is
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dynamically regulated at physiological conditions. 7SK snRNA
and HEXIM1 inhibit Cdk9 activity in an inactive HEXIM1/7SK/
P-TEFb complex (7–10). We show here that CTIP2 associates
with the inactive HEXIM1/7SK/P-TEFb complex, which is dis-
tinct from the previously described CTIP2-associated complex
containing chromatin-modifying enzymes (19). Our genome-
wide comparison of Cdk9- and CTIP2-sensitive cellular genes is
consistent with CTIP2 being a P-TEFb–repressive component.
Mechanistically, we observed that RNA Pol II Serine 2 phos-
phorylation levels increase in CTIP2-knockdown cells. In addition,
in vitro kinase assays identiﬁed CTIP2 as a direct inhibitor of
Cdk9 enzymatic activity. Based on these observations, we pro-
pose that, when associated with HEXIM1/7SK/P-TEFb, CTIP2
signiﬁcantly represses Cdk9 kinase activity and thus contributes
to the inhibition of P-TEFb function. Interestingly, the presence
of the 7SK snRNA is crucial for recruiting CTIP2 to P-TEFb.
CTIP2 is able to bind the 7SK snRNA in vitro and in vivo, sug-
gesting a direct interaction between both components. The 7SK
snRNA has been shown to have at least two major functions in
gene expression regulation: it negatively regulates P-TEFb activity
and it acts as a negative regulator of the architectural transcription
factor HMGA1 (31–34). However, whether CTIP2 impacts other
7SK-including complexes such as the 7SK/hnRNP (K, A1/A2, or
Q1/R) complexes (35) remains under question. Recently, mul-
tifunctional HIV-1 Tat-associated P-TEFb complexes were
identiﬁed. Tatcom2 includes the 7SK snRNA, LARP7 but not
HEXIM1, and Tatcom1 includes MLL-fusion partners and the
PAF1 complex (12). Preliminary results suggest that CTIP2 may
associate with PAF1 and LARP7 (Fig. S7). However, decipher-
ing the inﬂuence of Tat expression on the CTIP2/7SK/HEXIM1
complex and deﬁning the impact of CTIP2 on the Tat-associated
complexes will need more investigations. Interestingly, CTIP2
and HMGA1 both associate with the loop 2 region of 7SK RNA.
Moreover, preliminary data suggest that CTIP2 collaborates with
HMGA1 to inhibit HIV-1 gene transcription and the viral rep-
lication. Because we have also observed that endogenous CTIP2
represses the Tat/P-TEFb–mediated transactivation of the HIV-1
promoter (Fig. 1E), the repressive activity of CTIP2 and HMGA1
on this P-TEFb–sensitive promoter is now attested. In addition,
this control of P-TEFb might contribute to the persistence of the
latently infected HIV-1 reservoirs by counteracting the major
viral reactivation events. Although ∼50% of the cellular genes
were similarly modiﬁed upon CTIP2 overexpression or 7SK
knockdown, the remaining half showed an inverse correlation.
This subset of genes was identiﬁed as activated by CTIP2, but
repressed by 7SK RNA. These genes are likely regulated by
CTIP2 in a Cdk9-independent manner. D’Orso and Frankel
showed the recruitment of the inactive P-TEFb complex to the
Sp1 binding sites of the HIV-1 promoter (13). However, no
mechanistic evidence was provided on the way of this recruitment.
Because CTIP2 is anchored to the Sp1 region via an association
with Sp1 and LSD1 proteins (27, 36), CTIP2 may constitute a
platform for the recruitment of inactive P-TEFb to the HIV-1
promoter. Together with AIDS, hypertrophic cardiomyopathy is
a well-described P-TEFb–dependent pathology (for review, see
refs. 20 and 21). Upon HCM, the overexpression of the β-myosin
heavy chain induces an increase of the size of the sarcomeres and
a pathological thickening of the heart muscle. This ﬁnal target
gene expression is controlled by multiple pathways, all contrib-
uting to HCM (20). Our results suggest that CTIP2 contributes
to the control of the MAPK, the Ca2+/Calmodulin, the NF-κB/
NFAT, and the PI3K/AkT pathways. In addition, we show that
CTIP2 inhibits the expression of the β-myosin heavy chain
(MYH7) consistently with the repression of Cdk9 activity. More-
over, the CTIP2-mediated anchorage of an inactive P-TEFb
complex at the MYH7 promoter further argues for the presence
of the inactive P-TEFb complex at promoters of P-TEFb sensi-
tive genes. In fact, a recent study by Ji et al. has demonstrated
the assembly of 7SK RNA-containing complexes at gene pro-
moters (37). Taken together, our results suggest that CTIP2 is a
potent inhibitor of P-TEFb function in two of the best chara-
terized P-TEFb sensitive pathologies: HCM and AIDS. As a part
of the 7SK/HEXIM1/P-TEFb complex, CTIP2 controls P-TEFb–
sensitive gene expression and thereby may constitute a pharma-
ceutical target for ﬁghting P-TEFb–dependent pathologies.
Materials and Methods
Cell Culture. The human microglial cell line (provided by M. Tardieu, Paris,
France) (38) and HEK293T cell lines were maintained in Dulbecco’s modiﬁed
Eagle medium (DMEM) containing 10% (vol/vol) FCS and 100 U/mL penicillin/
streptomycin.
Coimmunoprecipitation Assays and Antibodies. Two days posttransfection,
immunoprecipitations were performed using the standard technique with
M2 anti-FLAG (Sigma), anti-Hexim1 (Abcam), or anti-CyclinT1 (Santa Cruz)
antibodies overnight at 4 °C with or without RNase or HMBA treatments.
Finally, the immunoprecipitated complexes were processed for SDS/PAGE
and Western blot analysis, real time quantitative PCR (qRT-PCR), or RT-
PCR assay. Proteins were detected in Western blot analyses using anti-
bodies directed against the FLAG epitope (M2 mouse monoclonal from
Sigma), CyclinT1 and Cdk9 (Santa Cruz), and CTIP2, Brd4, and HEXIM1
proteins (Abcam).
Gel Filtration Experiments. The 3 mg of microglial cellular nuclear extracts
were concentrated by using a Microcon YM-10 Centrifugal Filter Unit (3,000
Nominal Molecular Weight Limit) and separated by gel ﬁltration on a
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Fig. 6. CTIP2 binds to the MYH7 gene promoter region. (A) Cells were sub-
jected to chromatin immumoprecipitation experiments with the indicated
antibodies. The associated promoter region of the MYH7 gene was quantiﬁed
by Q-PCR. Enrichments are presented as % of input. (B) Cells transfected with
the control FLAG-pcDNA3 or the FLAG-CTIP2 plasmids were subjected to
chromatin immumoprecipitation experiments with the indicated antibodies 48
h posttransfection. The associated promoter, the −1,000 bp, the −2,000 bp, and
the +2,000 bp regions of the MYH7 gene were quantiﬁed by Q-PCR. Fold
enrichments are presented relative to the enrichments observed in the control
condition. Results are representative of at least three independent experiments.
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loop3
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7SK RNA
Fig. 7. Model for CTIP2-mediated repression of P-TEFb target genes. Bound
to target promoters, CTIP2 interacts with HEXIM1 and the 7SK snRNA to re-
press P-TEFb kinase activity and thus the expression of P-TEFb–sensitive genes.
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Superose 6 PC 3.2/30 column (Amersham Biosciences) as previously described
(39). The 29 fractions collected were accessed by SDS/PAGE and Western blot
analysis. Upon RT-PCR ampliﬁcation, the presence of the 7SK was visualized
by agarose gel electrophoresis.
Micro Scale Thermophoresis. Micro Scale Thermophoresis (MST) experiments
were conducted with Fam6-labeled 7SK L2 RNA or 7SK L2 m137 RNA and
increasing concentrations of FLAG-CTIP2 using a Monolith NT.115 (Nano-
temper Technologies) as described previously (40) (Laser-power 20%, Laser-
on time 60s, LED-power 30%).
Transcriptome Analyses. Transcriptome analyses were performed using either
Agilent Human whole-genome array (G2534-60011), Applied Biosystems
human arrays (Product nos. 4339628 and 4336875), or an Affymetrix Gen-
eChip MOE 430 2.0 array according to the manufacturer’s instructions. Data
quality was determined using a QC procedure (41). Data were normalized
using NeONORM with k = 0.02 (42–44). Subtraction proﬁling was performed
as in refs. 31 and 32 using the CDS test (45).
Generation of Cardiac Hypertrophic Mice. Micropumps (Alzet 2002 Osmotic
Pumps) were set up to deliver (R)-(-) Phenylephrine hydrochloride (Sigma
P6126-5G) at 80 mg·kg−1·day−1 or vehicle buffer only (PBS, 0.002% ascorbic
acid) for 15 d. The micropumps were implanted under the back skin of
ﬁve C57BL/6N mice for each group under 2% Isofurane (Abbott), 2% in
oxygen. Cardiac hypertrophy was validated by the increase of heart weight
to body weight ratio in treated animals. Protocols are in accordance with
the ethic recommendations of the Université Pierre et Marie Curie, Paris 6
University.
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